期刊文献+

探讨利用活化凝血时间监测进行血液透析过程普通肝素用量调整 被引量:3

To Explore the Monitor Excitation Blood Coagulation Time Adjust to Dosage of Unfractionated Heparin in Hematodialysis Process
下载PDF
导出
摘要 目的普通肝素是血液透析中常用的抗凝剂,使用剂量主要依据患者的症状及医生的经验,无法进行科学的数据评量。方法选取30位使用普通肝素的长期血透析患者,使用Hemochron 801凝血测试仪进行活化凝血时间的床边监测。结果肝素用量调整由66.6降至62.2IU/kg,活化时间由活化时间由(1.76±0.32)倍^(1.52±0.28)倍至(1.57±0.48)倍^(1.44±0.28)倍基础值,P<0.05,差异具有统计学意义。结论利用ACT测试可明确个体的肝素感受性及代谢速率差异,合理调整剂量以达到最佳化的肝素治疗效果,降低出凝血的风险,提供安全有效的血液透析治疗方案。 Objective Unfractionated heparin is commonly used anticoagulant in hemodialysis, the dose mainly based on patients symptoms and the experience of doctors, it has no scientiifc data assessment.Methods Selected 30 cases with long-term hemodialysis who had used unfractionated heparin, coagulation used Hemochron 801 tester activated clotting time bedside monitoring.Results The adjusted by the amount of heparin from 66.6 dropped 62.2 IU/kg, Activation time of (1.76±0.32)times, (1.52±0.28) baseline down to (1.57±0.48)times, (1.44 ± 0.28) times the baseline value, P〈0.05, had difference statistically significance.Conclusion ACT test sensitivity and heparin can understand individual differences in metabolic rate, reasonable adjustments to achieve the best of heparin, to avoid the risk of bleeding and clotting, provide safe and effective hemodialysis treatment.
出处 《中国继续医学教育》 2015年第29期161-163,共3页 China Continuing Medical Education
关键词 活化凝血时间 活化部份凝血活素时间 普通肝素 全身肝素化 Activated clotting time Activated part thromboplastin time Heparin Systemic heparin
  • 相关文献

参考文献8

  • 1Davenport A. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments[J]. Pediatr Nephrol, 2012, 27 ( 10 ) : 1869-1879.
  • 2Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients[J]. Semin Dial, 2009, 22 ( 3 ) : 279-286.
  • 3Sabovic M, Salobir B, Preloznik Zupan I, et al. The influence of the haemodialysis procedure on platelets, coagulation and flbrinolysis[J]. Pathophysiol Haemost Thromb, 2005, 34 ( 6 ) : 274-278.
  • 4Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAl-1) : a key factor linking fibrinolysis and age-related subclinical and clinical conditions[J]. Cardiovasc Ther, 2010, 28 (5): 72-91.
  • 5Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and physiologic functions of its main components[J]. Biochemistry ( Mosc ), 2002, 67 ( 1 ) .99-108.
  • 6Cairo MS, Allen J, Higgins C, et al. Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation[J]. Am J Pathol, 1983, 113 ( 1 ) : 67-74.
  • 7Shen JI, Mitani AA, Chang TI, et al. Use and safety of heparin- free maintenance hemodialysis in the USA[J]. Nephrol Dial Transplant, 2013, 28 ( 6 ) : 1589-1602.
  • 8Fourtounas C. Pharmacodynamics ofunfractionated heparin during and after a hemodialysis session: the impact of the administered dose[J]. Am J Kidney Dis, 2008, 52 ( 4 ) : 805-806.

同被引文献41

  • 1Davenport A. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments [- J 1. Pediatr Nephrol,2012, 27(10): 1869-1879.
  • 2陈香美.血液净化的抗凝治疗.见:陈香美,主编.血液净化标准操作规程(2010版)[M].北京:人民军医出版社,2010.46-47.
  • 3梅长林.抗凝.见:何长民,张训,闵志廉等,主编.肾脏替代治疗学[M].上海:上海科学技术出版社,1999.48-57.
  • 4钱家麒.血液透析的抗凝疗法.见:王海燕,主编.肾脏病学[M].第3版.北京:人民卫生出版社,2008.1968-1969.
  • 5Stasko J, Galajda P, Ivankova J, et al. Soluble P-selectin dur- ing a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment[J]. Clin Appl Thromb Hemost, 2007, 13(4):410-415.
  • 6Hertig A, Rondeau E. Role of the coagulation fibrinolysis sys- tem in fibrin-associated glomerular injury[J]. J Am Soc Neph- rol, 2004, 15(4): 844-853.
  • 7Molino D, De Santo NG, Marotta R, et al. Plasma levels of plasminogen activator inhibitor type 1, factor , prothrombin activation Fragment 1 + 2, anticardiolipin, and antiprothrom- bin antibodies are risk factors for thrombosis in hemodialysis patients[J]. Semin Nephrol, 2004, 24(5): 495-501.
  • 8戎殳.透析抗凝.见:梅长林,叶朝阳,戎殳等,主编.实用透析手册[M].第2版.北京:人民卫生出版社,2009.71-81.
  • 9汤光.抗凝血药.见:汤光,李大魁,主编.现代临床药物学[M].北京:化学工业出版社,2003.517~531.
  • 10王质刚.血液透析抗凝治疗中应注意的问题.见:王质刚,主编.血液净化学[M].第3版.北京:北京科学技术出版社,2010.114-115.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部